Regenerative Research Foundation
- Assets
- $4.5m
- Revenue
- $5.1m
- Investments
- $0.0
- Employees
- 43
- Location
- Rensselaer, NY
- Founding
- 11/2007
- Data as of
- 12/2021
- EIN
- 20-3654626
Organization Overview
Regenerative Research Foundation, operating under the name Neural Stem Cell Institute, is located in Rensselaer, NY. The organization was established in 2007. According to its NTEE Classification (H96) the organization is classified as: Neurology & Neuroscience Research, under the broad grouping of Medical Research and related organizations. As of 12/2021, Neural Stem Cell Institute employed 43 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Neural Stem Cell Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Neural Stem Cell Institute generated $5.1m in total revenue. The organization has seen a slow decline revenue. Over the past 7 years, revenues have fallen by an average of (3.0%) each year. All expenses for the organization totaled $4.6m during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (3.4%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE REGENERATIVE RESEARCH FOUNDATION CONTINUED TO SURMOUNT THE OPERATIONAL OBSTACLES CAUSED BY THE ONGOING COVID PANDEMIC AND SUCCESSFULLY PURSUE ITS RESEARCH AND DEVELOPMENT MISSION DURING 2021. RESEARCHERS AND SUPPORT STAFF RETURNED TO THE LABORATORIES WHILE FOLLOWING CDC AND NYS INFECTION CONTROL GUIDELINES. SIX ARTICLES REPORTED THE RESULTS OF RETINAL AND NEURAL RESEARCH STUDIES CONDUCTED BY FOUNDATION RESEARCHERS AND ANOTHER ANALYZING THE VALUE OF MENTORSHIP IN SCIENTIFIC CAREER DEVELOPMENT WERE PUBLISHED IN PROMINENT SCIENTIFIC JOURNALS DURING 2021. THESE ARTICLES ARE AVAILABLE FREE TO THE SCIENTIFIC COMMUNITY AND THE GENERAL PUBLIC THROUGH THE NATIONAL INSTITUTES OF HEALTH PUB-MED CENTRAL REPOSITORY. THE FOUNDATION RECEIVED A TOTAL OF 5 NEW AWARDS TO CONTINUE AND EXPAND ITS RETINAL AND DEMENTIA INVESTIGATIONS AND CONTINUED TO PREPARE AND SUBMIT APPLICATIONS TO SECURE ADDITIONAL FUNDING FOR FUTURE RESEARCH ACTIVITIES.
THE FOUNDATION CONTINUES ITS EFFORTS TO INITIATE A CLINICAL TRIAL TO TEST A PROMISING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION (AMD). THE PROGRAM HAS EXPERIENCED DELAYS CAUSED BY THE PANDEMIC, BUT THESE HAVE BEEN OVERCOME. IT IS EXPECTED THE CLINICAL TRIAL WILL BEGIN IN EARLY 2022. FINANCIAL AND OPERATIONAL SUPPORT FOR THE CLINICAL TRIAL WILL BE PROVIDED THROUGH A JOINT VENTURE BIOTECHNOLOGY COMPANY FORMED IN AUGUST 2019. THE FOUNDATION'S INVESTIGATORS SECURED A NEW SOURCE OF NIH FUNDING TO EXPAND THE RETINAL RESEARCH PROGRAM.
THE FOUNDATION'S ALZHEIMER'S DISEASE AND RELATED DEMENTIA RESEARCH PROGRAM CONTINUED AND EXPANDED DURING FISCAL YEAR 2021 DESPITE THE ONGOING PANDEMIC. NEW SOURCES OF FUNDING INCLUDING 4 NIH GRANTS WERE SECURED DURING THE YEAR IN SUPPORT OF THESE RESEARCH STUDIES WHICH WILL EXPAND THE SCIENTIFIC UNDERSTANDING OF THE DEVELOPMENT OF DEMENTIAS AND DISEASE PROGRESSION. THIS RESEARCH HAS DEVELOPED A POTENTIAL TREATMENT FOR DEMENTIA AND ASSOCIATED NEURODEGENERATIVE DISEASES WHICH WOULD BENEFIT THE WORLDWIDE AGING POPULATION.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Sally Temple-Stern PHD Scientific & Executive Dir | Officer | 65 | $178,091 |
Caitlin Hill Principal Investigator | 50 | $130,829 | |
Thomas Irwin Administrative Director | 36 | $103,424 | |
Jeffrey H Stern MD PHD Director For Translational Research | OfficerTrustee | 30 | $49,223 |
William Kahn CPA Chair | OfficerTrustee | 5 | $0 |
Vito Grasso Mpa Cae Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $4,136,716 |
| All other contributions, gifts, grants, and similar amounts not included above | $513,497 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $4,650,213 |
| Total Program Service Revenue | $281,050 |
| Investment income | $163 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $7,112 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $5,099,449 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $234,438 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $1,684,495 |
| Pension plan accruals and contributions | $169,152 |
| Other employee benefits | $52,482 |
| Payroll taxes | $140,384 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $159,144 |
| Fees for services: Accounting | $20,549 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $16,727 |
| Advertising and promotion | $0 |
| Office expenses | $43,357 |
| Information technology | $18,561 |
| Royalties | $0 |
| Occupancy | $340,639 |
| Travel | $9,856 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $12,238 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $83,635 |
| Insurance | $26,758 |
| All other expenses | $4,782 |
| Total functional expenses | $4,611,189 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $282,539 |
| Savings and temporary cash investments | $1,382,853 |
| Pledges and grants receivable | $939,297 |
| Accounts receivable, net | $92,222 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $139,782 |
| Net Land, buildings, and equipment | $119,505 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $1,562,563 |
| Total assets | $4,518,761 |
| Accounts payable and accrued expenses | $605,389 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $1,573,763 |
| Total liabilities | $2,179,152 |
| Net assets without donor restrictions | $1,454,706 |
| Net assets with donor restrictions | $884,903 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $4,518,761 |
Grants Recieved
Over the last fiscal year, we have identified 5 grants that Regenerative Research Foundation has recieved totaling $600,053.
| Awarding Organization | Amount |
|---|---|
Rainwater Charitable Foundation Fort Worth, TX PURPOSE: TAUOPATHY RESEARCH | $200,000 |
Rainwater Charitable Foundation Fort Worth, TX PURPOSE: TAUOPATHY RESEARCH | $200,000 |
Alzheimers Disease And Related Disorders Association Inc Chicago, IL PURPOSE: PROGRAM SUPPORT | $140,000 |
The Association For Frontotemporal Degeneration King Of Prussia, PA PURPOSE: PATHWAYS FOR HOPE PILOT GRANT - MEYSAM YAZDANKHAH | $60,000 |
Amazonsmile Foundation Seattle, WA PURPOSE: GENERAL SUPPORT | $53 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Winifred Masterson Burke Medical Research White Plains, NY | $9,563,124 | $17,375,898 |
Institute For Neurodegenerative Disorders Inc New Haven, CT | $7,010,755 | $8,708,583 |
Regenerative Research Foundation Rensselaer, NY | $4,518,761 | $5,099,449 |
Foundation For Neurologic Diseases Newburyport, MA | $42,372,654 | $7,178,078 |
Dent Neurosciences Research Center Inc Amherst, NY | $5,193,271 | $2,403,366 |
Harvard Neurodiscovery Center Inc Boston, MA | $3,333,990 | $139,693 |
Pediatric Neurotransmitter Disease Association Inc Farmingdale, NY | $0 | $2,481 |
Sumaira Foundation Somerville, MA | $356,004 | $309,923 |
International Behavioural And Neural Genetics Society Corporatio Wakefield, MA | $171,226 | $0 |
Chiari & Syringomyelia Research Foundation Inc West Seneca, NY | $321,935 | $0 |
Thames Neurological Institute Inc Norwich, CT | $2,632 | $13,042 |
Pennsylvania Neurological Society York, PA | $171,732 | $0 |